LAG3 and ovarian neoplasm: Dual blockade of PD-1 and LAG-3 can enhance T cell effector function, slow murine ovarian tumor growth, increase numbers of CD8+ T cells, and reduce the frequency of Tregs and MDSC in the peritoneal TME.